Metraipolis › archive › dc_71a5abb3fac1

Real-World Faricimab for Treatment-Naïve Neovascular AMD and Diabetic Macular Edema: 24-Month Outcomes from a Single-Center Pilot Cohort in South-Eastern Europe — Europe PMC PMID:42512849

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42512849
DOI
10.3390/medicina62071307
License (as archived)
solo-consultazione
Archived
2026-10-18T11:04:52.429Z
SHA-256 of the archived text
25f31445e2ec45aa353e1d6018d130e9a863877ba898cb66815e888a81421e72
Stable URL of this page
https://metraipolis.com/documento/dc_71a5abb3fac1

How to cite

Real-World Faricimab for Treatment-Naïve Neovascular AMD and Diabetic Macular Edema: 24-Month Outcomes from a Single-Center Pilot Cohort in South-Eastern Europe — Europe PMC PMID:42512849 — Europe PMC (en), https://europepmc.org/article/MED/42512849 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_71a5abb3fac1 (Metraipolis archive dc_71a5abb3fac1, sha256 25f31445e2ec45aa353e1d6018d130e9a863877ba898cb66815e888a81421e72)
BibTeX
@misc{dc71a5abb3fac1,
  title = {Real-World Faricimab for Treatment-Naïve Neovascular AMD and Diabetic Macular Edema: 24-Month Outcomes from a Single-Center Pilot Cohort in South-Eastern Europe — Europe PMC PMID:42512849},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42512849},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_71a5abb3fac1; sha256 25f31445e2ec45aa353e1d6018d130e9a863877ba898cb66815e888a81421e72},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42512849. Agents can read the archived copy with the MCP tool read_document.